Royalty Pharma plc (RPRX) key performance indicators and operating metrics (12 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Royalty Receipts | 887M | FY2026-Q1 |
| Adjusted EBITDA (non-GAAP) | 889M | FY2026-Q1 |
| Portfolio cash flow (adjusted EBITDA less net interest paid) | 722M | FY2026-Q1 |
| Portfolio receipts (total) | 925M | FY2026-Q1 |
| Net cash provided by operating activities | 718M | FY2026-Q1 |
| Milestones and other contractual receipts | 38M | FY2026-Q1 |
| Share count | 556.00 | FY2025-Q4 |
| Weighted-average diluted Class A ordinary shares outstanding | 556M | FY2025-Q4 |
| Royalty receipts growth (YoY) | 11.00 percent | FY2025-Q3 |
| Portfolio Receipts YoY growth | 11.00 percent | FY2025-Q3 |
| Net leverage | 2.90 ratio | FY2025-Q3 |
| Total leverage | 3.20 ratio | FY2025-Q3 |
Back to RPRX overview · RPRX earnings · RPRX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.